Middle Meatal Bacteriology During Acute Respiratory Infection in Children

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2007 by Oulu University Hospital.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
Oulu University Hospital
ClinicalTrials.gov Identifier:
NCT00545961
First received: October 17, 2007
Last updated: October 18, 2007
Last verified: October 2007
  Purpose

The purpose of this study is to find out whether the children with respiratory infection and the presence of pathogenic bacteria (S. pneumoniae, H. influenzae or M. catarrhalis) in the nasal middle meatus benefit from antimicrobial treatment.


Condition Intervention Phase
Acute Respiratory Infection
Sinusitis
Drug: placebo
Drug: amoxicillin clavulanate acid
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Clinical Relevance of Middle Meatal Bacteriology During Acute Respiratory Infection in Children - Randomised, Double-Blinded Clinical Study

Resource links provided by NLM:


Further study details as provided by Oulu University Hospital:

Primary Outcome Measures:
  • Duration of continuous daily symptoms of the acute respiratory infection diagnosed at the study entry. [ Time Frame: within the first 3 weeks after enrolment ]

Secondary Outcome Measures:
  • duration (days)and severity (grade mild, severe) of different symptoms (clear nasal discharge, coloured nasal discharge, nasal obstruction, cough, throat pain, ear ache, fever, headache, diarrhea) [ Time Frame: within the first three weeks after enrolment ]
  • number of days the child is using the following symptomatic drugs (pain killers, nasal vasoconstrictors, nasal corticosteroids, asthma drugs, antihistamines) [ Time Frame: within the first three weeks after the enrolment ]
  • number of days the child is not at school and that the parents are not at work [ Time Frame: within the first three weeks after enrolment ]

Estimated Enrollment: 120
Study Start Date: November 2007
Estimated Study Completion Date: December 2009
Arms Assigned Interventions
Placebo Comparator: 1
placebo Ora-Plus (registered trademark) mixture with an strawberry sweetening agent to make the placebo mixture similar in appearance and taste to active drug
Drug: placebo
mixture, 0.28125 ml/kg twice a day for 7 days
Other Name: Ora-Plus (registered trademark) mixture
Active Comparator: 2
amoxicillin-clavulanate acid
Drug: amoxicillin clavulanate acid
mixture 0.28125 ml / kg twice a day for 7 days
Other Name: Clavurion mixture (Orion Oy)

Detailed Description:

Acute sinusitis is one of the most common disease in children requiring antimicrobial treatment. The diagnosis and treatment outcomes of acute sinusitis are contradictory, and better diagnostic criteria are needed. In adults with acute maxillary sinusitis, bacterial culture results obtained from the nasal middle meatus are comparable to those obtained from sinus puncture and aspiration. In children, the presence of pathogenic bacteria (S. pneumoniae, H. influenzae or M. catarrhalis) in the nasal middle meatus during respiratory infection predicts longer duration of signs and symptoms of common cold.

In this randomized placebo-controlled study, the effect of the antimicrobial treatment (amoxicillin-clavulanate) is examined in children with pathogenic bacteria (S. pneumoniae, H. influenzae or M. catarrhalis) in the nasal middle meatus during respiratory infection. The duration of the symptoms and speed of recovery is recognized by daily symptom-diary, the results are compared between the treatment groups.

  Eligibility

Ages Eligible for Study:   6 Years to 13 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • acute respiratory infection with nasal symptoms (nasal obstruction or discharge)
  • seeking medical help from health centre for the respiratory symptoms
  • pathogenic bacteria (S pneumoniae, H influenzae or M catarrhalis) identified from right or left nasal middle meatus in the endoscopically taken swab culture sampling taken by a study investigator (all microbiological analyses are done by the National Public Health Institute´s microbiological laboratory in Oulu)

Exclusion Criteria:

  • otitis, tonsillitis or other disease requiring antimicrobial treatment
  • respiratory infection within 4 weeks of screening
  • antimicrobial treatment within 4 weeks of screening
  • allergy to penicillin or amoxicillin
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00545961

Contacts
Contact: Aila A Kristo, MD +35883153492 aila.kristo@ppshp.fi
Contact: Olli-Pekka Alho, MD +35883153473 olli-pekka.alho@oulu.fi

Locations
Finland
Keski-pohjanmaan keskussairaala Not yet recruiting
Kokkola, Finland
Sub-Investigator: Eeva Löfgren, MD         
Oulu University Hospital Not yet recruiting
Oulu, Finland
Principal Investigator: Aila Kristo, MD         
Sub-Investigator: Anna Marttila, MD         
Sub-Investigator: Ulla Lantto, MD         
Etelä-Pohjanmaan Keskussairaala Not yet recruiting
Seinäjoki, Finland
Sub-Investigator: Jukka-Pekka Kuusiniemi, MD         
Sponsors and Collaborators
Oulu University Hospital
Investigators
Principal Investigator: Jukka-Pekka Kuusiniemi, MD Dept of Otolaryngology, Seinäjoki Central Hospital, Finland
Principal Investigator: Eeva Löfgren, MD Dept of Otolaryngology, Kokkola Central Hospital, Finland
Principal Investigator: Anna Marttila, MD Dept of Otolaryngology, University of Oulu, Finland
Study Director: Olli-Pekka Alho, professor Dept of Otolaryngology, University of Oulu, Finland
Study Director: Aila Kristo, MD Dept of Otolaryngology, University of Oulu, Finland
Principal Investigator: Ulla Lantto, MD Dept of Otolaryngology, University of Oulu, Finland
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00545961     History of Changes
Other Study ID Numbers: Diary nr 41/2007
Study First Received: October 17, 2007
Last Updated: October 18, 2007
Health Authority: Finland: Finnish Medicines Agency

Keywords provided by Oulu University Hospital:
respiratory infection
sinusitis
rhinosinusitis
children
middle meatal specimens
respiratory track bacteria
amoxicillin-clavulanate
pneumococci
haemophilus
moraxella

Additional relevant MeSH terms:
Respiratory Tract Infections
Sinusitis
Infection
Respiratory Tract Diseases
Paranasal Sinus Diseases
Nose Diseases
Otorhinolaryngologic Diseases
Amoxicillin
Amoxicillin-Potassium Clavulanate Combination
Clavulanic Acids
Clavulanic Acid
Anti-Bacterial Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on July 10, 2014